Abstract: The invention relates to a process for producing formulations of sparingly water-soluble substances, said sparingly soluble substances being present in amorphous embedded form in a copolymer, and said copolymer being obtained by free-radically initiated polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the sum of components i), ii) and iii) equals 100% by weight, which comprises embedding the sparingly soluble substance into the copolymer at temperatures above the melting point of the sparingly soluble substances.

Abstract: A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl]benzenesulfonamide) stabilized by nanoparticles, particularly silica nanoparticles.

Abstract: A composition for preventing and treating fatty liver is disclosed. The composition includes a lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from the group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium nicotinate, chromium GTF, chromium yeast extract, other inorganic salts of trivalent chromium, other organic salts of trivalent chromium, and combinations thereof. The composition of the present invention can provide a beneficial effect in preventing and treating fatty liver by effectively reducing multiple risk factors of fatty liver disease.

Abstract: The invention relates to a cosmetic method for making-up and/or caring for keratin materials, in particular the skin, whereby a cosmetic composition is applied to the keratin materials, said cosmetic composition taking the form of an emulsion and comprising siloxane resins and a specific nonionic silicone surfactant. In particular, the invention relates to compositions used to care for or make-up the aforementioned keratin materials.

Abstract: The invention provides polymers and methods for their use. Specifically, certain embodiments of the present invention provide a polymer that comprises a plurality of salicylic acid-adipic (SA-Adipic) units of the following formula and a plurality of salicylic acid-diethylmalonic (SA-DEM) units of the following formula Certain embodiments of the invention also provide slow degrading microspheres comprising polymers described herein for undelayed and sustained drug delivery. Certain embodiments of the present invention provide methods for treating a chronic eye disease or arthritis in a patient, comprising administering to the patient a therapeutically effective amount of a polymer or microsphere as described herein.

Abstract: Described is a direct method for the fabrication of resorcinarene nanocapsules by photopolymerization of compounds of formula (I), such as resorcinarene tetraalkene tetrathiol (RTATT), in the absence of any template or preorganization. Further, by varying the polymerization media, a variety of other polymeric architectures like lattices, fibrous networks, and nanoparticles were obtained. The morphology and structure were characterized by transmission electron microscopy, energy dispersive spectroscopy, scanning electron microscopy, dynamic light scattering, infrared and nuclear magnetic resonance spectroscopy. These morphologically distinct resorcinarene polymeric architectures contain residual thiol and ene functional groups offering potential functionalization opportunities.

Abstract: The use of copolymers obtained by free-radical polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the total of components i), ii) and iii) equals 100% by weight, as solubilizers for slightly water-soluble substances.

Abstract: The methods described herein provide treatment of rosacea using topical formulations of dapsone. The methods also provide treatment of rosacea with topical dapsone in combination with other active agents, including metronidazole. The methods avoid negative hematologic side effects, including hemolysis and hemolytic anemia, that are associated with oral administration of dapsone.

Abstract: The present invention relates to a nanoparticulated anaesthetic composition for topical use in which at least one local anaesthetic agent is encapsulated in polymeric nanoparticles. The present invention also relates to the use of such polymeric nanoparticles comprising at least one local anaesthetic agent in the preparation of an anaesthetic composition for topical application to the skin or mucosa.

Abstract: A method for treating a wound, and a dressing for wound care management comprising a three-dimensional body of glass-based fibers comprising one or more glass-formers selected from the group consisting of P2O5, SiO2, and B2O3; at least about 25 wt % of the fibers have a diameter between about 200 nm and about 4000 nm, and a length:width aspect ratio of at least about 10. In another form, the glasses are in the form of particles in an ointment or cream applied to a wound. In yet other forms the glasses are employed as fibers formed into sutures for closing a wound, or as particles in a surgical glue for closing a wound.

Abstract: The invention relates to pressurized gas formulations for dosage aerosols, in which a medicament is formulated suspended in TG 227 ea (1,1,1,2,3,3,3-heptafluoropropane) and/or TG 134 a (1,1,1,2-tetrafluoroethane) as a propellant, and to their use for producing a medicament. The aerosol is preferably an inhalation aerosol.

Abstract: Micronized particles of a low-dosage strength active ingredient, to be used in dry powder formulations for inhalation, with particular properties can easily and homogenously disperse in a dry powder formulation to be administered by means of a dry powder inhaler device.

Abstract: Methods for enhancing a preference for a product by repetitive use. The method involves formulating a perfume composition into a product, the perfume composition including (I) allyl caproate and (II) ambroxan or geranium oil.

Abstract: An edible chew pill jacket receives a pill/tablet or capsule that is to be administered to a pet, animal or human. The edible chew pill jacket includes a flexible top wall, side walls and bottom wall configured to form a chamber appointed to receive a pill. A flexible longitudinal slit is integrated within the top wall for providing access to the chamber for insertion of the pill within the edible chew pill jacket. The edible chew pill jacket is formulated with at least one flavoring to provide a tasty treat appointed to mask the pill's taste. The chew pill jacket substantially encapsulates the pill/tablet appointed to be orally ingested. The chew pill jacket may include medicament therein, nutrients, vitamins, or may simply be provided as a tasty treat to mask the taste of the pill.

Abstract: The present invention relates to a re-applicable mascara composition containing a unique combination of a chemically modified wax and a polymeric film former including a copolymer of vinylpyrrolidone and aminoacrylates. The mascara composition of the present invention can be readily re-applied to eyelashes hours after the initial application to increase the lash volume, without the discomfort and clumping commonly caused by attempts to re-apply mascara to already-coated eyelashes.

Abstract: The invention provides a cellulose derivative having a repeating unit of the formula below, a composition including the cellulose derivative and a phospholipid, a method for production thereof, and an adhesion barrier including the cellulose derivative or the composition. In the formula, R1, R2, and R3 are —H, —CH2—COOH, —CH2—COOX, or —CH2CO-phosphatidylethanolamine, and X is an alkali metal or an alkali earth metal. The degree of substitution of —CH2—COOH and —CH2—COOX is 0.3 to 2.0 in total, and the degree of substitution of —CH2CO-phosphatidylethanolamine is 0.001 to 0.05.

Abstract: The invention relates to a method for sterilizing raw, unheated honey, wherein the raw, unheated honey is sterilized by ozonizing it by using an ozone generator. The invention also relates to a honey-based wound care preparation, wherein said preparation comprises raw, unheated ozonized honey that has been ozonized by a method according to the invention. The invention also relates to a wound care treatment product comprising a honey-based preparation, wherein the said wound care treatment product comprises a preparation according to the invention. Finally, the invention relates to a biscuit based on honey and food fibers and/or by-products of food fibers, wherein the biscuit is prepared from ozonized food fibers and/or by-products of food fibers and raw, unheated ozonized honey that has been ozonized by a method according to the invention.

Abstract: A hemostatic agent composition that includes a clay hemostatic agent which is inert and non-reactive relative to blood clotting proteins and platelets, yet is capable of accelerating the formation of a stable clot when applied to an actively bleeding wound.

Abstract: A hydrogen peroxide-containing composition comprising at least one antioxidant and at least one free radical scavenger operable to neutralize reactive oxygen species generated by the hydrogen peroxide and a method for stabilizing hydrogen peroxide containing compositions.

Abstract: There is disclosed a pharmaceutical composition comprising racemic aminopterin or pharmaceutically acceptable salts thereof. There is further disclosed a method to treat a disorder in a patient comprising administering a therapeutically effective amount of racemic aminopterin or pharmaceutically acceptable salts of racemic aminopterin. More particularly, there is disclosed a method for treating disorders modulated by at least dihydrofolate reductase activity, such as cancers and inflammatory disorders, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of racemic aminopterin or a pharmaceutically acceptable salt thereof.